ROME Therapeutics
Matthias Götte obtained his Ph.D. at the Max-Planck-Institute of Biochemistry in Martinsried, Germany. He was a member of the microbiology and immunology department at McGill University in Montreal from 2000 to 2014. Matthias was honored with the National Researcher Award from the Fund for Health Research of Quebec. In 2014, he relocated his laboratory to the University of Alberta and assumed the position as chair of the department of medical microbiology & immunology. His research focuses on the study of viral replication and its inhibition with direct-acting antivirals. While HIV and HCV were major themes in his time at McGill, he is now interested in viruses with high epidemic potential, including Ebola, Lassa, influenza and coronaviruses. His work on the mechanism of action of Remdesivir against SARS-CoV-2 provides a recent example. He has published approximately 130 peer-reviewed papers, reviews and book chapters in the field of virology and antivirals. His research program is funded through grants from the Canadian Institutes of Health Research, the Provincial Government of Alberta and contracts from industry.
This person is not in the org chart
This person is not in any offices
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.”